tasks, groups of 8 (7) tasks, groups of 4 (3) tasks, and groups of 2 (1) tasks, and measured performance by cross validation mean squared error of each drug. The values on top of each boxplot shows the P values for Wilcoxon signed--rank test when comparing the drug MSEs of each splitting scenario to those of the elastic net model. Figure S4 : Comparison of trace norm and kernelized--bayesian multitask learning on CCLE, NCI60 and CTD2 data sets Performance comparison of kernelized Bayesian multitask learning (kbmtl), and trace norm model in inductive setting in CCLE, NCI60 and CTD2 dataset. KBMTL's performance as measured by MSE, was comparable to trace norm multitask learning in the two smaller data sets CCLE (with 24 drugs, P = 0.282) and NCI60 (with 59 cell lines, P = 0.660, one--sided Wilcoxon signed rank test). However, we found that KBMTL has significantly weaker prediction performance in CTD2 (228 cell lines and 354 drugs), compared to the trace norm model (P < 3.55e--53). Figure S6 : Hierarchical clustering analysis for the CCLE data set Hierarchical clustering of CCLE drugs using weight vectors learned by elastic net and trace norm models. Figure S8 : Heatmap of elastic net weight vectors on the NCI60 data set Heatmap of NCI60 drugs using weight vectors learned by elastic net model. The large white space was caused by the sparsity of elastic net models for many drugs; dense models for other drugs were generated when α = 0 was chosen as optimal by glmnet, and thus they became ridge regression models. 
